1. TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study. (4th December 2022) Authors: Alvarez Secord, Angeles; Barroilhet, Lisa; Cheol Lim, Myong; Oosman, Sonia; Gupta, Sunil; Jada, Srinivasa; Gold, Michael; Gilbert, Lucy; Barlin, Joyce; Edraki, Babak; Tewari, Devansu; Provencher, Diane; Kim, Yong Man; Bixel, Kristin; O'Malley, David Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 3 Page Start: A233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. TP025/#1399 Artistry-7: phase 3 multicenter study of nemvaleukin alfa plus pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. (4th December 2022) Authors: Herzog, Thomas; Hays, John; Moore, Kathleen; Konstantinopoulos, Panagiotis; Gilbert, Lucy; Monk, Bradley; O'Malley, David; Barlin, Joyce; Rege, Jessicca; Desai, Monali; Du, Yangchun; Dalal, Rita; Coleman, Robert L; Sehouli, Jalid Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 3 Page Start: A235 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗